Mohd H Abdul-Aziz1,2, Helmi Sulaiman3, Mohd-Basri Mat-Nor4, Vineya Rai5, Kang K Wong5, Mohd S Hasan5, Azrin N Abd Rahman6,7, Janattul A Jamal8, Steven C Wallis9, Jeffrey Lipman9,10, Christine E Staatz7,11, Jason A Roberts12,13,14. 1. Burns, Trauma and Critical Care Research Centre, Level 3, Ned Hanlon Building, Royal Brisbane and Women's Hospital, The University of Queensland, Herston, QLD, 4029, Australia. mohd.abdulaziz1@uqconnect.edu.au. 2. School of Pharmacy, International Islamic University of Malaysia, Kuantan, Pahang, Malaysia. mohd.abdulaziz1@uqconnect.edu.au. 3. Infectious Diseases Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. 4. Department of Anaesthesiology and Intensive Care, School of Medicine, International Islamic University of Malaysia, Kuantan, Pahang, Malaysia. 5. Department of Anaesthesiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. 6. School of Pharmacy, International Islamic University of Malaysia, Kuantan, Pahang, Malaysia. 7. School of Pharmacy, The University of Queensland, Brisbane, Australia. 8. Department of Pharmacy, Hospital Tengku Ampuan Afzan, Kuantan, Malaysia. 9. Burns, Trauma and Critical Care Research Centre, Level 3, Ned Hanlon Building, Royal Brisbane and Women's Hospital, The University of Queensland, Herston, QLD, 4029, Australia. 10. Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia. 11. Australian Centre of Pharmacometrics, Brisbane, Australia. 12. Burns, Trauma and Critical Care Research Centre, Level 3, Ned Hanlon Building, Royal Brisbane and Women's Hospital, The University of Queensland, Herston, QLD, 4029, Australia. j.roberts2@uq.edu.au. 13. School of Pharmacy, The University of Queensland, Brisbane, Australia. j.roberts2@uq.edu.au. 14. Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia. j.roberts2@uq.edu.au.
Abstract
PURPOSE: This study aims to determine if continuous infusion (CI) is associated with better clinical and pharmacokinetic/pharmacodynamic (PK/PD) outcomes compared to intermittent bolus (IB) dosing in critically ill patients with severe sepsis. METHODS: This was a two-centre randomised controlled trial of CI versus IB dosing of beta-lactam antibiotics, which enrolled critically ill participants with severe sepsis who were not on renal replacement therapy (RRT). The primary outcome was clinical cure at 14 days after antibiotic cessation. Secondary outcomes were PK/PD target attainment, ICU-free days and ventilator-free days at day 28 post-randomisation, 14- and 30-day survival, and time to white cell count normalisation. RESULTS: A total of 140 participants were enrolled with 70 participants each allocated to CI and IB dosing. CI participants had higher clinical cure rates (56 versus 34 %, p = 0.011) and higher median ventilator-free days (22 versus 14 days, p < 0.043) than IB participants. PK/PD target attainment rates were higher in the CI arm at 100 % fT >MIC than the IB arm on day 1 (97 versus 70 %, p < 0.001) and day 3 (97 versus 68 %, p < 0.001) post-randomisation. There was no difference in 14-day or 30-day survival between the treatment arms. CONCLUSIONS: In critically ill patients with severe sepsis not receivingRRT, CI demonstrated higher clinical cure rates and had better PK/PD target attainment compared to IB dosing of beta-lactam antibiotics. Continuous beta-lactam infusion may be mostly advantageous for critically ill patients with high levels of illness severity and not receiving RRT. Malaysian National Medical Research Register ID: NMRR-12-1013-14017.
RCT Entities:
PURPOSE: This study aims to determine if continuous infusion (CI) is associated with better clinical and pharmacokinetic/pharmacodynamic (PK/PD) outcomes compared to intermittent bolus (IB) dosing in critically illpatients with severe sepsis. METHODS: This was a two-centre randomised controlled trial of CI versus IB dosing of beta-lactam antibiotics, which enrolled critically illparticipants with severe sepsis who were not on renal replacement therapy (RRT). The primary outcome was clinical cure at 14 days after antibiotic cessation. Secondary outcomes were PK/PD target attainment, ICU-free days and ventilator-free days at day 28 post-randomisation, 14- and 30-day survival, and time to white cell count normalisation. RESULTS: A total of 140 participants were enrolled with 70 participants each allocated to CI and IB dosing. CI participants had higher clinical cure rates (56 versus 34 %, p = 0.011) and higher median ventilator-free days (22 versus 14 days, p < 0.043) than IB participants. PK/PD target attainment rates were higher in the CI arm at 100 % fT >MIC than the IB arm on day 1 (97 versus 70 %, p < 0.001) and day 3 (97 versus 68 %, p < 0.001) post-randomisation. There was no difference in 14-day or 30-day survival between the treatment arms. CONCLUSIONS: In critically illpatients with severe sepsis not receiving RRT, CI demonstrated higher clinical cure rates and had better PK/PD target attainment compared to IB dosing of beta-lactam antibiotics. Continuous beta-lactam infusion may be mostly advantageous for critically illpatients with high levels of illness severity and not receiving RRT. Malaysian National Medical Research Register ID: NMRR-12-1013-14017.
Authors: William K Lau; David Mercer; Kamal M Itani; David P Nicolau; Joseph L Kuti; Debra Mansfield; Adrian Dana Journal: Antimicrob Agents Chemother Date: 2006-08-28 Impact factor: 5.191
Authors: Mohd H Abdul-Aziz; Jeffrey Lipman; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Joel Dulhunty; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jason A Roberts Journal: J Antimicrob Chemother Date: 2015-10-03 Impact factor: 5.790
Authors: Janattul-Ain Jamal; Darren M Roberts; Andrew A Udy; Mohd-Basri Mat-Nor; Fariz-Safhan Mohamad-Nor; Steven C Wallis; Jeffrey Lipman; Jason A Roberts Journal: Int J Antimicrob Agents Date: 2015-03-28 Impact factor: 5.283
Authors: Joel M Dulhunty; Jason A Roberts; Joshua S Davis; Steven A R Webb; Rinaldo Bellomo; Charles Gomersall; Charudatt Shirwadkar; Glenn M Eastwood; John Myburgh; David L Paterson; Therese Starr; Sanjoy K Paul; Jeffrey Lipman Journal: Am J Respir Crit Care Med Date: 2015-12-01 Impact factor: 21.405
Authors: Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman Journal: Clin Infect Dis Date: 2014-01-14 Impact factor: 9.079
Authors: Ivan Chytra; Martin Stepan; Jan Benes; Petr Pelnar; Alexandra Zidkova; Tamara Bergerova; Richard Pradl; Eduard Kasal Journal: Crit Care Date: 2012-06-28 Impact factor: 9.097
Authors: Sofie Dhaese; Aaron Heffernan; David Liu; Mohd Hafiz Abdul-Aziz; Veronique Stove; Vincent H Tam; Jeffrey Lipman; Jason A Roberts; Jan J De Waele Journal: Clin Pharmacokinet Date: 2020-10 Impact factor: 6.447
Authors: Mohammad H Al-Shaer; Michael N Neely; Jiajun Liu; Kartikeya Cherabuddi; Veena Venugopalan; Nathaniel J Rhodes; Kenneth Klinker; Marc H Scheetz; Charles A Peloquin Journal: Antimicrob Agents Chemother Date: 2020-08-20 Impact factor: 5.191
Authors: D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern Journal: Anaesthesist Date: 2019-10 Impact factor: 1.041
Authors: Joan Antoni Schoenenberger-Arnaiz; Faten Ahmad-Diaz; Mar Miralbes-Torner; Ana Aragones-Eroles; Manuel Cano-Marron; Mercedes Palomar-Martinez Journal: Eur J Hosp Pharm Date: 2019-02-27
Authors: A Brinkmann; A C Röhr; A Köberer; T Fuchs; J Preisenberger; W A Krüger; O R Frey Journal: Med Klin Intensivmed Notfmed Date: 2016-09-13 Impact factor: 0.840